Cell dynamics in disease and therapy

我们的计划支持和鼓励临床科学家探索细胞动力学的潜力，以识别和评估生物标志物和治疗人类疾病的目标。该领域包括基因组动力学和移动的细胞区室，但也包括心肌细胞和神经元，两者都是具有特定要求的可兴奋细胞种类。该计划的参与者在其居住期间专门致力于开发具有竞争力的研究计划。他们利用尖端技术来研究疾病相关的细胞改变和操纵它们进行治疗的选择。我们的项目建立在并显著扩展了为临床医生科学家建立的外部资助的小规模项目，以及与知名研究财团的互动，例如新成立的卓越集群2067“多尺度生物成像：从分子机器到可兴奋细胞网络”，由德国癌症援助组织新资助的综合癌症中心，以及哥廷根大学医学中心（UMG）的四个合作研究中心和三个研究单位。该计划的主要特点已被证明是特别有帮助的。这些措施包括：由外部审查员透明地选择候选人;候选人与临床和科学主管的强制性协议;以几个月为单位的受保护的研究时间，包括外部研究轮换的选择;与哥廷根的马克斯·普朗克研究所合作;严格的质量管理;以及指导和辅导的最佳实践模式。尽管发生了流行病，我们项目的参与者还是去了外部研究机构，例如哈佛医学院和当地的马克斯·普朗克研究所。一些第一批科学出版物记录了他们的成功，尽管大多数成员参与不到一年。外部审查和咨询委员会继续通过视频会议开展活动，我们主要资格课程的教员也是如此。在新的资助期内，我们将尽一切努力进一步鼓励我们计划的成员与导师和同事进行个人互动，无论他们位于何处，以充分利用科学讨论和合作的机会。这将包括由参与者组织的科学大会，基于我们过去建立的类似大会的令人印象深刻的成功。我们将使该计划成为UMG的永久机构，让未来几代临床科学家追求雄心勃勃的转化研究。这将使他们能够为我们对基于细胞的疾病机制以及当地和全球健康的知识做出重大贡献。

Our program supports and encourages Clinician Scientists who explore the potential of cell dynamics to identify and evaluate biomarkers and targets to treat human diseases. This field includes genome dynamics and mobile cellular compartments, but also cardiomyocytes and neurons, both excitable cell species with specific requirements. The participants of the program dedicate >18 months during their residency exclusively to develop a competitive research program. They take advantage of cutting edge technologies to study disease-associated cellular alterations and options to manipulate them for therapy. Our program builds upon and significantly expands established, externally funded, small-scale programs for Clinician Scientists, and upon the interaction with high-profile research consortia, e.g. the newly established Cluster of Excellence 2067 “Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells”, the Comprehensive Cancer Center newly funded by the German Cancer Aid, as well as four Collaborative Research Centers and three Research Units of University Medical Center Göttingen (UMG). Key features of the program have proven to be particularly helpful. Those include transparent selection of candidates by external reviewers; mandatory agreements of candidates with clinical and scientific supervisors; protected research time in blocks of several months, including the option of external research rotations; collaboration with Max Planck Institutes in Göttingen; rigorous quality management; and best-practice models of guidance and mentoring. Despite the pandemics, the participants of our program went for external research stays, e.g. at Harvard Medical School and at local Max Planck Institutes. A number of first scientific publications are documenting their success, although most members were participating for less than a year. The external review and advisory board has continued its activity through videoconferences, and so did the instructors of our key qualification courses. Within the new funding period, we will make every effort to further encourage the members of our program towards personal interactions with mentors and colleagues, wherever located, to fully exploit the opportunities for scientific discussions and collaborations. This will include a scientific congress organized by the participants, based on the impressive success of a similar congress that we set up in the past. We will make this program a permanent institution at UMG, allowing future generations of Clinician Scientists to pursue ambitious translational research. This will enable them to make strong contributions to our knowledge on cell-based disease mechanisms as well as to local and global health.